These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 34070765)

  • 1. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.
    Palmiero G; Cesaro A; Vetrano E; Pafundi PC; Galiero R; Caturano A; Moscarella E; Gragnano F; Salvatore T; Rinaldi L; Calabrò P; Sasso FC
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs.
    Packer M
    Cardiovasc Diabetol; 2020 May; 19(1):62. PubMed ID: 32404204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.
    Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits.
    Preda A; Montecucco F; Carbone F; Camici GG; Lüscher TF; Kraler S; Liberale L
    Cardiovasc Res; 2024 Apr; 120(5):443-460. PubMed ID: 38456601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment.
    Rizzo MR; Di Meo I; Polito R; Auriemma MC; Gambardella A; di Mauro G; Capuano A; Paolisso G
    Pharmacol Res; 2022 Feb; 176():106062. PubMed ID: 35017046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis.
    Gronda E; Lopaschuk GD; Arduini A; Santoro A; Benincasa G; Palazzuoli A; Gabrielli D; Napoli C
    Can J Physiol Pharmacol; 2022 Feb; 100(2):93-106. PubMed ID: 35112597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors.
    Packer M
    Eur J Heart Fail; 2020 Apr; 22(4):618-628. PubMed ID: 32037659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
    Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
    Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.
    Nikolic M; Zivkovic V; Jovic JJ; Sretenovic J; Davidovic G; Simovic S; Djokovic D; Muric N; Bolevich S; Jakovljevic V
    Heart Fail Rev; 2022 May; 27(3):935-949. PubMed ID: 33534040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors.
    Al Thani NA; Hasan M; Yalcin HC
    J Cardiovasc Transl Res; 2023 Oct; 16(5):975-986. PubMed ID: 37052784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?
    Pabel S; Hamdani N; Luedde M; Sossalla S
    Curr Heart Fail Rep; 2021 Oct; 18(5):315-328. PubMed ID: 34523061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
    Liu Z; Ma X; Ilyas I; Zheng X; Luo S; Little PJ; Kamato D; Sahebkar A; Wu W; Weng J; Xu S
    Theranostics; 2021; 11(9):4502-4515. PubMed ID: 33754074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential anti-arrhythmic effect of SGLT2 inhibitors.
    Duan HY; Barajas-Martinez H; Antzelevitch C; Hu D
    Cardiovasc Diabetol; 2024 Jul; 23(1):252. PubMed ID: 39010053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
    Bhatia K; Jain V; Gupta K; Bansal A; Fox A; Qamar A; Damman K; Vaduganathan M
    Eur J Heart Fail; 2021 Jun; 23(6):1002-1008. PubMed ID: 33609071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors.
    Packer M
    Circ Heart Fail; 2020 Sep; 13(9):e007197. PubMed ID: 32894987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.